Alasdair is a leader in KPMG's Healthcare and Life Sciences Strategy practice. He has over 20 years experience in strategy consulting specializing in inorganic growth and commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. As a trained cancer biologist Alasdair helps clients solve complex business problems that require deep scientific and technical knowledge. A particular focus is in cell and gene therapies across both in vivo and ex vivo approaches and all modalities and therapy areas. Alasdair has supported biopharmaceutical clients across the entire cell and gene ecosystem, from manufacturing strategy, to inorganic growth strategy and commercial due diligence on targets for R&D and business development teams, through to commercial launch support, including distribution, supply chain and pricing. He has also led numerous buy-side commercial due diligence projects for private investors looking to deploy capital in the cell and gene space. He has also authored a thought leadership piece on the challenges in "one-and-done" gene therapies and what these mean for biopharmaceutical companies looking to build a presence in this innovative space.